LATEST DEAL TYPE
LATEST DEAL AMOUNT
Developer of a next-generation cell and gene therapies created to extend adoptive immunotherapy to every patient with cancer. The company's next-generation cell and gene therapies with pharmacologic operating systems provide exquisite control of protein activity in cells and create adoptive cell therapies with new functions that are under control of the treating physician using simple, safe, orally-active, marketed drugs, enabling patients to improve on the current generation of cell therapies.
Privately Held (backing)
Other Pharmaceuticals and Biotechnology
1030 Massachusetts Avenue
Cambridge, MA 02138
Questions or concerns about this profile? Reach out to email@example.com